Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Blood (2025) 146 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2025-LBA-3

Published: 2025

Journal Articles

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2025-2215

Published: 2025

Journal Articles

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Blood (2025) 146 (Supplement 1): 5815.

https://doi.org/10.1182/blood-2025-5815

Published: 2025

Journal Articles

Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)

Blood (2025) 146 (Supplement 1): 370.

https://doi.org/10.1182/blood-2025-370

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Ciara Louise Freeman, Sarah Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Johanna Groeneveld, Sarah Johnston, Timothy Pulham, Sandy Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel

Blood (2025) 146 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2025-4079

Published: 2025

Journal Articles

Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study)

Blood (2025) 146 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2025-5435

Published: 2025

Journal Articles

KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel

Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay Nooka, Salomon Manier, Shinsuke Iida, Sophie Hello, Devender Dhanda, Prachi Ghodke, Martina Raggi, Roland Marion Gallois, Jaclyn Davis, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2297.

https://doi.org/10.1182/blood-2025-2297

Published: 2025

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Yoshiaki Marumo, Masaki Ri, Toru Ebina, Tomoyuki Nakamura, Hirokazu Sasaki, Shiori Kinoshita, Tomoko Narita, Tomotaka Suzuki, Takaomi Sanda, Takanori Nanri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 2411.6.

https://doi.org/10.1182/blood-2024-200675

Published: 2024

Journal Articles

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Blood (2024) 144 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2024-200354

Published: 2024

Journal Articles

Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma

Toru Ebina, Masaki Ri, Yoshiko Oshima, Tomoyuki Nakamura, Yoshiaki Marumo, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2024-199941

Published: 2024

Journal Articles

Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Blood (2024) 144 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2024-198992

Published: 2024

Journal Articles

Stratifying ‘frail’ Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes

Yukiyasu Kato, Tomotaka Suzuki, Aki Kondo, Naohiro Matsunaga, Takaki Kikuchi, Takashi Kanamori, Takashi Yoshida, Satoshi Kayukawa, Yu Asao, Hiroki Yano, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 3342.

https://doi.org/10.1182/blood-2024-201310

Published: 2024

Journal Articles

Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy

Tomoyuki Nakamura, Masaki Ri, Toru Ebina, Yoshiaki Marumo, Yoshiko Oshima, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Takaomi Sanda, Hirokazu Komatsu, Yasumichi Inoue, Hidetoshi Hayashi, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 6813.

https://doi.org/10.1182/blood-2024-200981

Published: 2024

Journal Articles

Genetic Alterations in Primary and Secondary Plasma Cell Leukemia: A Comparative Study Involving Patients with Non-PCL Myeloma

Yoko Nakanishi, Tomotaka Suzuki, Takashi Kanamori, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2024-200672

Published: 2024

Journal Articles

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sueh-Li Lim, Bradley Augustson, Hira S Mian, Edward A. Stadtmauer, Shinsuke Iida, Michael Slade, Saswati Hazra, Kamal Chamoun, Patricia Cheung, Jamal Saeh, Nina Shah, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 2000.2.

https://doi.org/10.1182/blood-2024-207816

Published: 2024

Journal Articles

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2024-205872

Published: 2024

Journal Articles

The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma

Tomotaka Suzuki, Keiichiro Fujii, Naohiro Matsunaga, Hirokazu Sasaki, Takashi Kanamori, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki

Blood (2024) 144 (Supplement 1): 3075.

https://doi.org/10.1182/blood-2024-198325

Published: 2024

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study)

KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma

Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Stratifying ‘frail’ Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes

Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy

Genetic Alterations in Primary and Secondary Plasma Cell Leukemia: A Comparative Study Involving Patients with Non-PCL Myeloma

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only